<img src="https://ws.zoominfo.com/pixel/H4QRKGJNZm52yFBaHe9u" width="1" height="1" style="display: none;">
Contact Us

The Problem with Decentralized Clinical Trials & How to Solve for Success

3 minute read

As of October 2022, there are approximately 430,800 (YTD) clinical studies registered globally. The number of trials has significantly grown since 2,119 registrations in 2000. Hospitals and clinics are leveraging connected devices more and more, and market research is indicating that there is accelerated adoption and growth opportunities for clinical trials.

So, what are decentralized clinical trials? There are two different types of DCT models: hybrid and fully decentralized clinical trials. Hybrid models are as they sound – elements include both traditional in-person and virtual visits. One primary difference is the use of handheld mobile devices and connected medical devices such as blood pressure cuffs, blood glucose meters, and more. Fully virtual clinical trials are 100 percent remote with no clinician-to-patient interaction. This model relies on e-visits and video teleconferencing for patient engagement.

Barriers and Breakthroughs

DCT practice began prior to the COVID-19 pandemic, but the connected health industry began to see a majority shift to clinical trials in 2020. According to McKinsey & Company, telehealth utilization was 78 times higher after April 2020 than in February 2020.

The benefits of DCTs are invaluable – improved accuracy in readings, increased patient retention, and real-time communications are all important factors that IoT contributes to this market. A Mobile Health in Clinical Trials Survey Report conducted by SCORR Marketing and Applied Clinical Trials found that 35.2 percent of respondents reported improved data quality, 28.5 percent reported improved patient engagement, and 12.3 percent reported improvement in patient recruitment.

However, benefits come with barriers, and knowing how to solve for success is crucial. There are several IoT challenges that can delay deployment: device management, regulation and compliance, network security, and hardware selection to name a few. Some key factors to consider when deploying DCTs are site feasibility, robust technology, data strategy, and site staff training.

KORE Bridges the Gap

KORE partners with global healthcare providers to deploy connectivity in over 165 countries, with 200+ clinical trials supported, and more than 60,000 devices sustained. Our award-winning Connected Health Telemetry Solution brides the technology gap from patients to healthcare applications. Are you ready for decentralized clinical trials? Take our short readiness assessment here.

And for more information on how to solve for success in DCTs, watch our on-demand webinar, “The Problem with Decentralized Clinical Trials & How to Solve for Success,” with KORE EVP of Connected Health, Bryan Lubel, and Parexel Sensor Solutions Director, Nathan Noakes, here.

New call-to-action

Topic(s): Healthcare , Featured

U3GM Blog Post Comments


Stay up to date on all things IoT by signing up for email notifications.